DOCK STORY

DOCKET NO.: CBDL-0056

10/517909NT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Martine Barth, et al.

Confirmation No.: Not Yet Assigned

Application No.: 10/517,909

Group Art Unit: Not Yet Assigned

Filing Date: December 9, 2004

Examiner: Not Yet Assigned

For: NOVEL ARYLSULPHONAMIDE DERIVATIVES AND THEIR USE IN

THERAPY

DATE OF DEPOSIT: April 11, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450().

TYPED NAME: Wendy A. Cho REGISTRATION NO.: 36,697

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

	the above identified application as set forth in § 1.491, before the mailing date
	of a first Office Action on the merits of the above-identified application, or
	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of $\underline{\$180.00}$ as set forth in \S 1.17(p).
\boxtimes	Copies of reference numbers 1 thru 18 listed on the attached Form PTO-1449
	are enclosed herewith.
	Copies of reference numbers - on the attached Form PTO 1449
	are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application.

Enclosed is a copy of the PCT International Search report dated **November 25, 2003**, which indicates relevance of the references.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: April 11, 2005

Wendy A. Choi

Registration No. 36,697

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW

Form 1	orm r i CJ-1449 Monthen		Docket No CBDL-00		Application No. 10/517,909			
C	ited b	and Publications y Applicant heets if necessary)	Applicant Martine Barth, et al.					
U.S. Department of Commerce Patent and Trademark Office			Filing Date December		Group Not Yet Assigned			
O	ГНЕБ	R DOCUMENTS (Includ	ing Author	, Title, Date, I	Pertinent Pages, Etc.)			
	1	Dutta, A.S. et al., "Inhibitors of Porcine Pancreatic Elastase. Peptides Incorporating α-Aza-amino Acid Residues in the P1 Position", <i>Journal of the Chemical Society</i> , Perkin Transactions 1, 1986 , 9, 1655-1664						
*	2	Wagner, G., et al., "Synthesis of n-(Tosyl-beta-alanyl)-n-(Tosyl-beta-alanyl)-und N(Tosyl aminocapronyl) effectively Thrombininhibitoren amidinophenylalaninamiden as profile, <i>Pharmazie</i> , 1984, 39(5), 315-317						
	3	Voigt, B, G. Wagner, "Synthesis vona (Arysulfonyl I prolyl) vona-(Arysulfonyl-L-prolyl)-und well-Benzyloxycarbonyl-l-prolyl)-D, L-4-Amidinophenyl-Alaninamiden as Thrombininhibitoren ", <i>Pharmazie</i> , 1986, 41(4), 233-235 No English Language abstract available						
	4	Shibata, M. et al., "Modi <i>Pain</i> , 38, 347-352	fied Formal	in Test: Charac	cteristic Biphasic Pain Response",			
		*			. ×			
EXAMINER	_			DATE CONS	SIDERED			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. CBDL-0056	Application No. 10/517,909			
				Applicant Martine Barth, et al.				
				Filing Date Coup December 9, 2004 Group Not Yet Assigned			l ·	
		U. S	S. PATENT	DOCUMENTS	•			
Examiner Initial		Document No.	Date	Name		Class	Subclass	
		FORE	IGN PATI	ENT DOCUMENTS				
Examiner Initial		Document No.	Date	Country		Tra YES	nslation NO	
	5	EP 0 236 163 B1	10/30/90	ЕРО				
	6	EP 0 614 911 B1	04/28/99	ЕРО				
	7	EP 0236 164 B1	09/12/90.	EPO	4			
	8	EP 0558 961 A2	09/08/93	EPO				
· · · · · · · · · · · · · · · · · · ·	9	WO 00/34313	06/15/00	PCT				
	10	WO 00/75107 A2	12/14/00	PCT				
	11	WO 02/076964 A1	10/03/02	PCT				
	12	WO 92/16549 A1	10/01/92	PCT				
	13	WO 96/40639	12/19/96	PCT				
	14	WO 97/24349	07/10/97	PCT				
	15	WO 97/25315	07/17/97	PCT				
-	16	WO 98/03503	01/29/98	PCT				
	17	WO 98/24783	06/11/98	PCT				
	18	WO 99/00387	01/07/99	PCT				
EXAMINE	R			DATE CONSIDER	RED			

7